|

VERT-002 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: PFL-002

Pipeline

Phase 1/2: 1

Top Sponsors

  • Pierre Fabre Medicament1

Indications

  • MET Alteration1
  • Solid Tumor1
  • Lung Cancer1
  • Cancer1

Washington D.C., District of Columbia1 trial

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

Georgetown Lombardi Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.